Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Date:10/22/2008

ilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

The Company will hold a conference call with research analysts at 8 a.m. Eastern Daylight Time today. The purpose of the call is to review the financial results of the Company for the 2008 third quarter and first nine months. Interested investors and others may listen to the call live or on a delayed basis through the Internet webcast, which may be accessed by visiting the Company's Internet Web site at http://www.wyeth.com and clicking on the "Investor Relations" hyperlink.

Also, for recent announcements and additional information, including product sales information, please refer to the Company's Internet Web site.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... RESEARCH TRIANGLE PARK, N.C. and ... -- Leading agricultural research firm AgBiome, and Genective, key ... partnership to accelerate the discovery of new generations ... new traits for insect control to counter the ... to partner with Genective, aligning AgBiome,s unique insect ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... , July 1, 2015 InferMed ... technology will ... evidence-based clinical s olutions suite   ... and medical information products and services, announced today the acquisition ... decision support (CDS) technology company. InferMed,s Arezzo technology ...
(Date:6/30/2015)... KYOTO, Japan , July 1, 2015 R-Japan ... Act on the Safety of Regenerative Medicine from the Ministry ... Welfare on June 29, 2015. The fact ... cell processing facility through the auditing from Pharmaceuticals and Medical ... filing the application, allows it to provide stem cell manufacturing ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a ... of technologies targeting the chronic inflammation,underlying cardiovascular and ... CEO, will present a Company Overview at BIO,CEO ... York City, at 11:00,a.m. (ET) on Tuesday, February ...
... Feb. 5 EntreMed, Inc.,(Nasdaq: ENMD ) ... of cancer and inflammatory diseases, today,announced that James ... a Corporate overview at the BIO CEO and ... February 11-13, 2008. Mr. Burns,presentation is scheduled for ...
... to Advise on Development of New Drug ... Candidate to Treat Autoimmune Disease -, SAN ... development company, announced today that it,has appointed the first five ... protein licensed from Amgen in December 2007 for,the treatment of ...
Cached Biology Technology:Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3EntreMed to Present at BIO CEO and Investor Conference 2Anthera Pharmaceuticals Forms Scientific Advisory Board 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... between researchers at the Hebrew university of Jerusalem and ... treatment of brain diseases. The researchers found that TyrNovo,s ... process of aging in order to protect the brain ... first and important step towards the development of future ...
... two-thirds (65%) of Americans say it,s likely there ... ahead as Congress continues to debate deficit and ... opinion poll commissioned by Research!America and the American ... party affiliations: Democrats (66%), Republicans (65%) and Independents ...
... and environmental organisations are working together to influence future ... English Channel is used daily by more than 500 ... shores in Southern England and Northern France, and it ... Now 12 organisations, led by Plymouth University, have ...
Cached Biology News:New compound for slowing the aging process can lead to novel treatments for brain diseases 2New compound for slowing the aging process can lead to novel treatments for brain diseases 3Majority of Americans believe another government shutdown likely in coming months 2Majority of Americans believe another government shutdown likely in coming months 3Anglo-French partnership develops guidance on future management of English Channel 2
... This antibody is specific for human cardiac troponin ... the Ca-binding signals responsible for contraction of cardiac ... troponin complex in human cells. It also cross-reacts ... Antigen: Highly purified human ...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White ... INERT GAS. A cell-permeable, reversible inhibitor of ... x-40 (ED 50 = 2.6 ... = 2.7 μM) in HEK293 cells ...
cystatin A (N-18)...
...
Biology Products: